← Leaderboards
Patrice Mimche
University Of Utah
$4,267,251
Attributed
$5,416,036
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,416,036 · 3
By mechanism
R01$4,844,161 · 2
R21$571,875 · 1
Top collaborators
- Sihem Boudina4 shared
Most similar at University Of Utah
Same institution · by research overlap
- A Gordon Smith$10,319,540
- John Robinson Singleton$10,547,748
- Sihem Boudina$6,642,517
- Julio Cesar Facelli$3,592,616
- Ramkiran Gouripeddi$1,129,764
Others in their field
Other Emerging Leaders on “Ephrins”
- Sana D Karam · University Of Colorado Denver$4,039,397
- Catherine Kehsin Cheng · Scripps Research Institute, The$2,835,445
- Makoto Inoue · University Of Illinois At Urbana-Champaign$1,904,814
- Omar Franco Coronel · Louisiana State Univ Hsc Shreveport$1,818,795
- Kristopher Kahle · Massachusetts General Hospital$1,294,807
- Joshua P Sasine · University Of California Los Angeles$1,284,535
Research focus
EphrinsBiological ProcessSignaling MoleculeAngiogenesisReceptorFibrosisLigandsReceptor Protein-Tyrosine KinasesWound HealingTransdifferentiationPathway InteractionsPreventFibrogenesisFda ApprovedEphb2 ReceptorCellsInflammationMyofibroblastSignal TransductionMouse ModelMembranePlayMolecular WeightCollagen
Grant awards (14)
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$555,833
R01 · FY2025 · DK · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$335,251
R01 · FY2025 · AR · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$274,167
R01 · FY2025 · AR · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$538,034
R01 · FY2024 · DK · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$560,483
R01 · FY2023 · DK · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$345,620
R01 · FY2023 · AR · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$599,169
R01 · FY2022 · DK · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$342,164
R01 · FY2022 · AR · contact PI
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)$599,884
R01 · FY2021 · DK · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$335,251
R01 · FY2021 · AR · contact PI
EphB/EphrinB signaling in Systemic Sclerosis$358,305
R01 · FY2020 · AR · contact PI
EphB2 receptor tyrosine kinase in liver fibrosis$190,625
R21 · FY2020 · DK · contact PI
EphB2 receptor tyrosine kinase in liver fibrosis$190,625
R21 · FY2019 · DK · contact PI
EphB2 receptor tyrosine kinase in liver fibrosis$190,625
R21 · FY2018 · DK · contact PI